The predictive role of peripheral blood immune cell subsets in the immune-related adverse events for non-small cell lung cancer
10.13431/j.cnki.immunol.j.20250072
- VernacularTitle:外周血免疫细胞亚群对非小细胞肺癌免疫治疗相关不良反应的预测作用
- Author:
Xu JIANG
1
;
Jiana CHEN
;
Huaxia YANG
Author Information
1. 中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室,转化医学基础设施临床研究所生物标志物平台,北京 100730
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
immune checkpoint inhibitors;
immune-related adverse events;
immune cell subsets
- From:
Immunological Journal
2025;41(7):495-500
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the predictive value of baseline peripheral blood immune cell profiles for immune-related adverse events(irAEs)following immune checkpoint inhibitors(ICIs)therapy for non-small cell lung cancer(NSCLC)patients.Methods In total,45 NSCLC patients who received ICIs treatment between December 2023 and December 2024 were enrolled.Patients were stratified into irAE(n=19)and non-irAE(n=26)groups based on irAE occurrence during treatment.Pre-treatment peripheral blood samples were collected,and flow cytometry was used to quantify immune subset proportions and activation marker expression.Receiver operating characteristic(ROC)curves were used to evaluate the predictive value of individual cellular markers for irAE development in NSCLC patients after immunotherapy.Results The irAE group exhibited significantly reduced proportion of intermediate monocytes(CD14+CD16+),as compared with the non-irAE group(P<0.05).The expression of CD69,an early activation marker,in CD3+T lymphocytes and the expression of CD154,an early activation marker,in CD8+T lymphocytes were both significantly lower in the irAE group than in the non-irAE group(P<0.05).ROC analysis demonstrated better predictive performance of the three-marker panel(intermediate monocytes/CD69+CD3+T cells and CD154+CD8+T cells;AUC=0.778)compared with individual biomarkers.Conclusion Lower levels of intermediate monocytes,CD69+CD3+T cells,and CD154+CD8+T cells in baseline peripheral blood may serve as potential biomarkers for predicting irAE development in NSCLC patients after immunotherapy.
